|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0022646,
umls-concept:C0035015,
umls-concept:C0079004,
umls-concept:C0087111,
umls-concept:C0205178,
umls-concept:C0220825,
umls-concept:C0393022,
umls-concept:C0450127,
umls-concept:C1521725,
umls-concept:C1548437,
umls-concept:C1709854,
umls-concept:C1882923
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2011-4-21
|
|
pubmed:abstractText |
Recently published pediatric trial of Rituximab for the treatment of CD20+ acute renal allograft rejection (AR) demonstrated transient depletion of circulating/intragraft B cells (Zarkhin et al., Am J Transplant 2008; 8: 2607). In this study, we have evaluated phenotypic definition of circulating B-cell subsets before and after standard of care and B-cell depletional AR therapies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/B-Cell Activating Factor,
http://linkedlifedata.com/resource/pubmed/chemical/B-Cell Activation Factor Receptor,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Steroids,
http://linkedlifedata.com/resource/pubmed/chemical/TNFRSF13C protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/TNFSF13B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1534-6080
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1010-8
|
|
pubmed:meshHeading |
pubmed-meshheading:21403590-Acute Disease,
pubmed-meshheading:21403590-Adolescent,
pubmed-meshheading:21403590-Age Factors,
pubmed-meshheading:21403590-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:21403590-B-Cell Activating Factor,
pubmed-meshheading:21403590-B-Cell Activation Factor Receptor,
pubmed-meshheading:21403590-B-Lymphocyte Subsets,
pubmed-meshheading:21403590-Child,
pubmed-meshheading:21403590-Child, Preschool,
pubmed-meshheading:21403590-Female,
pubmed-meshheading:21403590-Graft Rejection,
pubmed-meshheading:21403590-Humans,
pubmed-meshheading:21403590-Immunologic Memory,
pubmed-meshheading:21403590-Immunosuppressive Agents,
pubmed-meshheading:21403590-Infant,
pubmed-meshheading:21403590-Kidney Transplantation,
pubmed-meshheading:21403590-Lymphocyte Depletion,
pubmed-meshheading:21403590-Male,
pubmed-meshheading:21403590-Phenotype,
pubmed-meshheading:21403590-Steroids,
pubmed-meshheading:21403590-Viremia,
pubmed-meshheading:21403590-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients.
|
|
pubmed:affiliation |
Currently, Stanford University, Palo Alto, CA 94304, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
